Phaseline

Companies › Risen (Suzhou) Pharma Tech

Risen (Suzhou) Pharma Tech: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 1 Phase 3, 1 Phase 1, 1 Phase 2; Oncology, Neurology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JS105
PIK3CA inhibitor
PIK3CAPhase 3Breast Cancer; Advanced Solid TumorsFeb 2027
RP902–Phase 2Mild Cognitive Impairment (MCI)May 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06208410JS105Phase 1Advanced Solid TumorsOncologyFeb 2027
NCT07579884RP902Phase 2Mild Cognitive Impairment (MCI)NeurologyMay 2029
NCT07207070JS105Phase 3Breast CancerOncologyMay 2029

Targets

PIK3CA (1)

Companies with the same targets

Eli Lilly Novartis Recursion Pharmaceuticals TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Totus Medicines iOnctura Restorbio Roche Haihe Biopharma Faeth Therapeutics

Companies built like this

iOnctura AB Science Italfarmaco Faeth Therapeutics SK Life Science

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.